Immunome (IMNM) Receivables (2020 - 2021)

Immunome (IMNM) reported Receivables of $13.3 million for Q1 2021, little changed quarter-over-quarter from $13.3 million in Q4 2020.

Immunome (IMNM) Receivables (2020 - 2021) Analysis & Trends

Immunome has reported Receivables for 2 years, with the latest figure at $13.3 million in Q1 2021.

For the quarter ending Q1 2021, Receivables changed N/A year-over-year to $13.3 million; the trailing twelve-month figure through Mar 2021 stood at $13.3 million (changed N/A YoY), and the FY2020 full-year result was $13.3 million, changed N/A from the prior year.
Receivables for Q1 2021 stood at $13.3 million, roughly flat from $13.3 million in the prior quarter.
The five-year high for Receivables was $13.3 million in Q3 2020, with the low at $13.3 million in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	13.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	2.00 Bn
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Immunome	2.12 Bn	1.54 Bn	-	-

Download Data